- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population‐based cancer registry data in <scp>J</scp>apan from 1993 to 2006
-
- Dai Chihara
- Division of Epidemiology and Prevention Aichi Cancer Center Research Institute Nagoya Japan
-
- Hidemi Ito
- Division of Epidemiology and Prevention Aichi Cancer Center Research Institute Nagoya Japan
-
- Koji Izutsu
- Department of Hematology Toranomon Hospital Tokyo Japan
-
- Masakazu Hattori
- Department of Cancer Therapy Center Fukui Prefectural Hospital Fukui Japan
-
- Yoshikazu Nishino
- Division of Cancer Epidemiology and Prevention Miyagi Cancer Center Research Institute Natori Japan
-
- Akiko Ioka
- Center for Cancer Control and Statistics Osaka Medical Center for Cancer and Cardiovascular Diseases Osaka Japan
-
- Tomohiro Matsuda
- Division of Surveillance Center for Cancer Control and Information Services, National Cancer Center Osaka Japan
-
- Yuri Ito
- Center for Cancer Control and Statistics Osaka Medical Center for Cancer and Cardiovascular Diseases Osaka Japan
Search this article
Description
<jats:p>There have been significant advances in the treatment of patients with lymphoma and myeloma. Although the improvements in survival outcome have been clearly addressed by clinical trials, these studies includes patients who are otherwise healthy and would be eligible for trials that the actual improvement in survival in the general patient population over time is yet to be elucidated. Therefore, we reviewed the cancer‐registry data of patients with lymphoma and myeloma in Japan from 1993 to 2006 and estimated relative survival (adjusted for competing causes of death in same‐age members of the general population) according to three periods of diagnosis (1993–1997, 1998–2002 and 2003–2006). We also estimated conditional 5‐year relative survival (5‐year survival rate of patients who have survived 5 years). A total of 26,141 patients were reviewed and analyzed. Relative survival improved in Hodgkin lymphoma (HL, <jats:italic>N</jats:italic> = 853, +20% improvement), diffuse large B‐cell lymphoma (DLBCL, <jats:italic>N</jats:italic> = 4,919, +14% improvement) and follicular lymphoma (FL, <jats:italic>N</jats:italic> = 1,333, +13% improvement). In contrast, we found no significant improvement in survival since 1993 in peripheral T‐cell lymphoma (PTCL, <jats:italic>N</jats:italic> = 667, +4% improvement), adult T‐cell leukemia/lymphoma (ATLL, <jats:italic>N</jats:italic> = 2,166, −5% improvement) or multiple myeloma (MM, <jats:italic>N</jats:italic> = 4,914, −2% improvement). Conditional 5‐year survival of HL, DLBCL, FL, PTCL, ATLL and MM was 88, 87, 79, 63, 53 and 45%, respectively. Relative survival of patients with HL, DLBCL and FL significantly improved from 1993 to 2006 in Japan; in contrast, no improvement was seen in other diseases, suggesting unmet need of novel treatment strategies.</jats:p>
Journal
-
- International Journal of Cancer
-
International Journal of Cancer 137 (5), 1217-1223, 2015-02-26
Wiley
